Allogene Corp - ALLO Revenue Dynamics YoY (Last Twelve Months)

Graphic logo of Allogene Corp (ALLO)

Allogene Therapeutics (ALLO) relies on the defensive status of biomedicine, which remains independent of macroeconomic trends. Relative revenue growth over the last four quarters compared to last year is reflected in the price action, where the -99.60 mark serves as a current indicator. The company strives for leadership in creating affordable "off-the-shelf" CAR-T products, overcoming pressure from resource behemoths and intense patent battles.

Allogene Therapeutics (ALLO): Sales Growth YoY (TTM) from 02/11/2024 to 11/18/2026

Allogene Corp (ALLO) - metric breakdowns and financial figures

- stock price and consensus target price:
Fundamental company valuation:Allogene Therapeutics
Flagship merchandise of Allogene Therapeutics Inc

This indicator measures revenue expansion rates over the last twelve months, allowing for an assessment of operational dynamics and the risk of an overvalued asset. Analysis of the rolling annual sales growth for Allogene Therapeutics (ALLO) reflects the success of clinical developments and partnerships—rather than market cyclicality—which drive fundamental growth within the non-cyclical cancer cell therapy sector.